AMMONIA N 13 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ammonia N 13, and when can generic versions of Ammonia N 13 launch?
Ammonia N 13 is a drug marketed by 3d Imaging Drug, Biomedcl Res Fdn, Brigham Womens Hosp, Cardinal Hlth 414, Central Radiopharm, Decatur, Essential Isotopes, Feinstein, Gen Hosp, Ionetix, Johns Hopkins Univ, Kreitchman Pet Ctr, Mcprf, Methodist, Midwest Medcl, Mips Crf, Ncm Usa Bronx Llc, Nukemed, Petnet, Precision Nuclear, Shertech Labs Llc, Sofie, Ucla Biomedical, Ucsf Rodiopharm, Univ Alahama Birm, Univ Tx Md Anderson, Univ Tx Sw Medctr, Univ Wisconsin, Wa Univ Sch Med, and Wisconsin. and is included in thirty-one NDAs.
The generic ingredient in AMMONIA N 13 is ammonia n-13. There are two drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ammonia n-13 profile page.
Summary for AMMONIA N 13
US Patents: | 0 |
Applicants: | 30 |
NDAs: | 31 |
Finished Product Suppliers / Packagers: | 21 |
Raw Ingredient (Bulk) Api Vendors: | 6 |
Clinical Trials: | 100 |
Patent Applications: | 829 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in AMMONIA N 13? | AMMONIA N 13 excipients list |
DailyMed Link: | AMMONIA N 13 at DailyMed |
Recent Clinical Trials for AMMONIA N 13
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Khyber Medical College, Peshawar | Phase 4 |
Cairo University | Phase 3 |
Medical University of Graz | Phase 4 |
Pharmacology for AMMONIA N 13
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Radiopharmaceutical Activity |